parahemophilia
defici
fv
result
mutat
clot
factor
gene
larg
major
bleed
disord
tabl
replac
defici
coagul
factor
protein
requir
prevent
revers
acut
bleed
episod
achiev
administr
recombin
plasmaderiv
clot
factor
concentr
pdcfc
eg
fviii
fix
inhibitorbypass
agent
rfviia
factor
viii
inhibitor
bypass
activ
feiba
effect
prevent
treat
bleed
patient
hemophilia
enabl
selfadministr
home
pdcfc
replac
cryoprecipit
fresh
frozen
plasma
thu
revolution
hemophilia
treatment
develop
countri
howev
cryoprecipit
fresh
frozen
plasma
still
use
develop
countri
initi
larg
blood
donor
pool
use
prepar
pdcfc
pathogen
screen
test
avail
result
infect
bloodborn
pathogen
major
concern
patient
hemophilia
particularli
relat
human
immunodefici
viru
hiv
hepat
c
viru
hcv
risk
hepat
b
viru
hbv
infect
reduc
substanti
vaccin
preval
hepat
b
surfac
antigen
among
european
blood
donor
current
around
mani
patient
sever
hemophilia
infect
hiv
contamin
fviii
fix
patient
sever
hemophilia
infect
hcv
contamin
plasmaderiv
fviii
high
rate
infect
associ
signific
mortal
itali
hiv
hcv
associ
hemophilia
death
respect
great
britain
mortal
patient
hemophilia
hiv
peak
versu
patient
hemophilia
without
hiv
coinfect
netherland
hemophilia
death
relat
hiv
hcv
complic
hivhcv
coinfect
us
hivrel
diseas
account
death
patient
hemophilia
today
risk
contract
hbv
hiv
hcv
transfus
blood
product
almost
elimin
develop
countri
plasma
collect
special
center
continu
inspect
european
medicin
agenc
ema
us
food
drug
administr
fda
prior
approv
commerci
use
plasma
screen
donat
rescreen
minipool
nucleic
acid
test
avail
virus
hiv
hepat
viru
hbv
hcv
parvoviru
describ
detail
plasma
master
file
approv
everi
year
regulatori
agenc
product
treat
solventdeterg
superh
day
pasteur
nanofilt
howev
despit
precaut
risk
nonenvelop
viru
infect
persist
eg
parvovirus
picornavirus
circovirus
characterist
patient
receiv
clot
factor
chang
year
improv
treatment
qualiti
avail
led
increas
life
expect
patient
hemophilia
itali
life
expect
peopl
hemophilia
year
versu
year
us
median
age
death
nonhivinfect
patient
hemophilia
year
life
expect
patient
hemophilia
netherland
year
improv
surviv
led
increas
agerel
clinic
problem
eg
comorbid
subsequ
increas
risk
infect
pathogen
dissemin
factor
concentr
consumpt
exposur
differ
product
batch
also
increas
due
chang
hemophilia
treatment
pattern
increas
use
prophylaxi
higher
rate
surgeri
elderli
increas
use
highdos
regimen
achiev
immun
toler
patient
develop
inhibitor
approx
patient
treat
pdcfc
recombin
product
alongsid
chang
patient
demograph
level
exposur
clot
factor
product
pathogen
agent
concern
also
chang
sever
emerg
viral
nonvir
pathogen
identifi
genet
factor
immunodefici
may
affect
risk
acquir
infect
clinic
outcom
environment
chang
increas
likelihood
contact
transmiss
certain
pathogen
sinc
possibl
screen
donor
blood
emerg
pathogen
system
place
immedi
withdraw
product
made
blood
donor
follow
confirm
suspect
pathogen
transmiss
major
consequ
patient
depend
product
caus
shortag
delay
suppli
particularli
market
reliant
singl
supplier
problem
may
caus
procedur
identifi
infect
product
batch
recal
specif
batch
identifi
test
patient
known
expos
manufactur
test
distribut
new
batch
exampl
ema
posit
statement
cjd
plasmaderiv
urinederiv
medicin
product
state
strong
evid
vcjd
transmiss
transfus
blood
plasma
product
view
lack
adequ
inform
vcjd
prudent
recal
batch
plasmaderiv
medicin
product
donor
plasma
pool
subsequ
develop
vcjd
unconfirm
definit
suspect
vcjd
identifi
among
blood
donor
itali
italian
pharmaceut
agenc
aifa
line
ema
posit
statement
prohibit
use
specif
batch
italian
blood
donor
recal
distribut
batch
requir
warehous
stock
distribut
consequ
product
shortag
meant
affect
hemophilia
patient
switch
altern
mostli
recombin
fviii
product
concern
regard
pathogen
safeti
blood
pdcfc
increas
demand
transfus
product
led
develop
recombin
coagul
factor
product
inevit
avoid
risk
bloodrel
pathogen
transmiss
inde
evid
date
pathogen
transmiss
use
product
howev
remain
potenti
risk
reagent
use
manufactur
recombin
product
exampl
cell
cultur
media
growth
factor
reagent
contain
protein
human
anim
origin
requir
undergo
risk
assess
prion
thirdgener
recombin
product
contain
anim
human
compon
therefor
carri
known
pathogen
transmiss
risk
recombin
agent
offer
inher
low
pathogen
risk
import
rememb
like
manufactur
process
extern
contamin
occur
seen
product
recombin
glucocerebrosidas
patient
gaucher
diseas
halt
result
viral
vesiviru
contamin
product
facil
genzym
corpor
usa
acut
shortag
therapeut
enzym
occur
direct
consequ
spite
wide
avail
recombin
factor
pdcfc
continu
need
first
unlik
patient
hemophilia
treat
recombin
product
forese
futur
second
recombin
product
avail
bleed
disord
tabl
final
econom
pressur
countri
meant
use
pdcfc
encourag
despit
improv
safeti
bloodand
plasmaderiv
recombin
coagul
factor
product
product
probabl
never
complet
safe
term
pathogen
risk
pharmacovigil
system
therefor
urgent
requir
european
union
monitor
longterm
qualiti
safeti
pdcfc
recombin
product
giovanni
